Can-Fite's oral psoriasis drug nears first independent look at Phase III data
Can-Fite BioPharma says the first 247 patients in its piclidenoson trial have finished treatment, setting up an outside-panel review of interim results in early 2027.
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Can-Fite BioPharma has reached the point in its late-stage psoriasis programme where outsiders will first see how the drug is performing. On 18 November 2026 the company said the 247th patient in the opening group of its Phase III trial of oral piclidenoson had received a last dose, which fixes the dataset for a planned interim review.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Can-Fite BioPharma Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
17 Nov 2026 · Adagene Inc. ADAG · Company news
Pipeline & R&D
MAIA reports 88% disease control for ateganosine-cemiplimab in third-line NSCLC
17 Nov 2026 · MAIA Biotechnology, Inc. MAIA · Company news